Literature DB >> 16966523

Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.

Susan H Fox, Naomi P Visanji, Tom H Johnston, Jordi Gomez-Ramirez, Valerie Voon, Jonathan M Brotchie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16966523     DOI： 10.1001/archneur.63.9.1343

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  19 in total

Review 1.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

Review 2.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

3.  The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.

Authors:  Adjia Hamadjida; Stephen G Nuara; Nicolas Veyres; Imane Frouni; Cynthia Kwan; Lamia Sid-Otmane; Mery-Jane Harraka; Jim C Gourdon; Philippe Huot
Journal:  Psychopharmacology (Berl)       Date:  2017-01-27       Impact factor: 4.530

Review 4.  Non-motor features of Parkinson disease.

Authors:  Anthony H V Schapira; K Ray Chaudhuri; Peter Jenner
Journal:  Nat Rev Neurosci       Date:  2017-06-08       Impact factor: 34.870

Review 5.  The use of nonhuman primate models to understand processes in Parkinson's disease.

Authors:  Javier Blesa; Inés Trigo-Damas; Natalia López-González Del Rey; José A Obeso
Journal:  J Neural Transm (Vienna)       Date:  2017-03-29       Impact factor: 3.575

Review 6.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 7.  The benefits of pramipexole selection in the treatment of Parkinson's disease.

Authors:  Mine Silindir; A Yekta Ozer
Journal:  Neurol Sci       Date:  2014-07-20       Impact factor: 3.307

8.  Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.

Authors:  Adjia Hamadjida; Stephen G Nuara; Dominique Bédard; Imane Frouni; Cynthia Kwan; Jim C Gourdon; Philippe Huot
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-07       Impact factor: 3.000

9.  Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.

Authors:  Adjia Hamadjida; Stephen G Nuara; Jim C Gourdon; Philippe Huot
Journal:  J Neural Transm (Vienna)       Date:  2017-12-15       Impact factor: 3.575

10.  Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.

Authors:  Cynthia Kwan; Stephen G Nuara; Jim C Gourdon; Philippe Huot
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-05-08       Impact factor: 3.000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.